Doxycycline

Generic Name: Doxycycline

Brand Names: Acticlate, Adoxa, Apprilon, Atridox, Doryx, Doxy, Doxycin, Lymepak, Mondoxyne, Monodox, Morgidox, Okebo, Oracea, Periostat, Targadox, Vibramycin

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₄N_₂O_₈

CAS Number: 564-25-0

Unique Ingredient Identifier: 334895S862

Background: Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is...

Indication: Doxycycline is indicated for the treatment of various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria, including:

It is also used to treat infections caused by the following gram-negative microorganisms:

Associated Conditions: Acinetobacter Infections, Anthrax, Bacterial Infection caused by Enterobacter aerogenes, Bartonellosis, Brucellosis, Campylobacter Infection, Chancroid, Chlamydia Trachomatis Infection, Early Lyme Disease, Granuloma Inguinale, Infection Due to Escherichia Coli, Inhalational Anthrax, Klebsiella Infections, Lymphogranuloma Venereum, Malaria caused by Plasmodium falciparum, Nongonococcal urethritis, Plague caused by Yersinia pestis, Psittacosis, Rectal infection caused by Chlamydia Trachomatis, Relapsing fever caused by Borrelia recurrentis, Respiratory Tract Infection Bacterial, Rickettsial infectious disorders, Severe Acne, Sexually Transmitted Infections (STIs), Shigella Infection, Trachoma inclusion conjunctivitis, Tularemia, Vibrio Cholerae Infection, Acute Intestinal amebiasis, Susceptible Bacterial Infections, Uncomplicated endocervical infection, Uncomplicated urethral infection

Associated Therapies: -

Clinical Trials

Daily Doxycycline to Inform Sexually Transmitted Infection Prophylaxis Regimens

Phase 4

Recruiting

Conditions: Sexually Transmitted Infection

Interventions: Drug: Doxycycline

First Posted Date: 2024-08-09

Last Posted Date: 2024-10-01

Lead Sponsor: Emory University

Target Recruit Count: 20

Registration Number: NCT06545656

Locations: 🇺🇸
Hope Clinic, Atlanta, Georgia, United States

Comparison Between Continuous and Pulsed Oral Doxycycline Treatment Protocols for Refractory Meibomian Gland Dysfunction

Completed

Conditions: Meibomian Gland Dysfunction
Blepharitis
Doxycycline Adverse Reaction

Interventions: Drug: Doxycyclin

First Posted Date: 2024-07-25

Last Posted Date: 2024-07-25

Lead Sponsor: University of Milan

Target Recruit Count: 65

Registration Number: NCT06520007

Locations: 🇮🇹
ASST Santi Paolo e Carlo - Ospedale San Paolo, Milano, MI, Italy

Characterization of Tuberculosis Associated Lung Fibrosis and Respiratory Impairment, and Prevention Using Doxycycline

Phase 2

Not yet recruiting

Conditions: Tuberculosis, Pulmonary

Interventions: Drug: Placebo
Drug: Doxycycline

First Posted Date: 2024-06-27

Last Posted Date: 2024-06-27

Lead Sponsor: Makerere University

Target Recruit Count: 200

Registration Number: NCT06477185

Locations: 🇺🇬
Makerere University Lung Institute, Kampala, Uganda

NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline

Phase 2

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: Doxycyclin

First Posted Date: 2024-06-11

Last Posted Date: 2024-07-03

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 50

Registration Number: NCT06452394

Locations: 🇨🇭
Kantonsspital St.Gallen, St. Gallen, SG, Switzerland
🇨🇭
Clinique de Genolier, Genolier, VD, Switzerland
🇨🇭
Kantonsspital Graubünden, Chur, GR, Switzerland

and more 4 locations

Adjunctive Doxycycline for Central Nervous System Tuberculosis

Phase 2

Not yet recruiting

Conditions: Tuberculosis; Meningoencephalitis (Etiology)
Tuberculosis, Meningeal
Tuberculosis; Meningitis (Etiology)
Tuberculosis, Central Nervous System

Interventions: Drug: Placebo
Drug: Doxycycline
Drug: Anti Tuberculosis Drug
Drug: Adjunctive corticosteroid

First Posted Date: 2024-06-06

Last Posted Date: 2024-06-06

Lead Sponsor: National University Hospital, Singapore

Target Recruit Count: 200

Registration Number: NCT06446245

Locations: 🇸🇬
National University Hospital, Singapore, Singapore

An Oral Doxycycline Regimen to Prevent Bacteremia Following Dental Procedures

Phase 4

Not yet recruiting

Conditions: Bacteremia
Endocarditis

Interventions: Drug: Clindamycin
Drug: Doxycycline

First Posted Date: 2024-05-20

Last Posted Date: 2024-06-17

Lead Sponsor: University of Santiago de Compostela

Target Recruit Count: 150

Registration Number: NCT06422221

Locations: 🇪🇸
Santiago de Compostela University Hospital, Santiago De Compostela, A Coruña, Spain

Doxycycline in Type II Diabetes

Phase 1

Recruiting

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Sitagliptin 100mg
Drug: Doxycyclin

First Posted Date: 2024-03-26

Last Posted Date: 2024-07-16

Lead Sponsor: Mostafa Bahaa

Target Recruit Count: 60

Registration Number: NCT06329882

Locations: 🇪🇬
Tanta Unuversity, Tanta, Egypt

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

Phase 2

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Amivantamab
Drug: Lazertinib
Drug: Doxycycline
Drug: Minocycline
Drug: Clindamycin
Drug: Chlorhexidine
Other: Noncomedogenic skin moisturizer

First Posted Date: 2023-11-07

Last Posted Date: 2024-12-05

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 200

Registration Number: NCT06120140

Locations: 🇺🇸
USC Norris Oncology Hematology Newport Beach, Newport Beach, California, United States
🇺🇸
Kaiser Permanente Oakland Medical Center, Oakland, California, United States
🇺🇸
Kaiser Permanente Roseville Medical Center, Roseville, California, United States

and more 90 locations